Deborah J. Andrews, Chief Financial Officer and Executive Vice President of STAAR Surgical Co (NASDAQ:STAA), filed a Form 4 on August 18, 2026, reporting multiple equity transactions dated August 14, 2026, including the vesting of performance stock units, tax withholding of shares, and the grant of new restricted stock units and stock options.

Key Highlights

  • PSU vesting: 5,233 performance stock units from the 2025 PSU Program vested on August 14, 2026, representing the third tranche of Andrews's new hire grant.
  • Tax withholding: 2,662 shares were withheld at $26.18 per share to satisfy tax obligations related to the PSU vesting.
  • New RSU grant: 4,975 restricted stock units were granted on August 14, 2026, vesting one-third on the first anniversary of the grant date, with the remainder vesting in 24 substantially equal monthly installments.
  • Stock option grant: An option to purchase 8,952 shares of common stock was granted, exercisable at $26.18, vesting over three years on the same schedule as the RSUs, with an expiration date of August 13, 2036.
  • Performance option grant: A performance stock option to purchase 29,159 shares was granted at $26.18, subject to stock-price hurdles of $50.00, $75.00, and $100.00 per share, expiring August 13, 2036.
  • Resulting ownership: Following all reported transactions, Andrews directly holds 38,910 shares of common stock.

Details of Deborah Andrews's August 2026 Equity Transactions at STAAR Surgical

According to the filing, the August 14, 2026 transactions began with the settlement of the third tranche of performance stock units under the 2025 PSU Program, which was part of Andrews's new hire grant. The filing states that "the number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals." Of the 5,233 shares that vested, 2,662 were withheld at a price of $26.18 per share to cover tax obligations, leaving Andrews with a direct holding of 38,910 shares of common stock following the transactions.

On the same date, the filing reports that Andrews received three new equity awards. The first is a grant of 4,975 restricted stock units, each representing the right to receive one share of STAAR Surgical common stock upon vesting. The vesting schedule calls for one-third on the first anniversary of the August 14, 2026 grant date, and the remaining two-thirds in 24 substantially equal monthly installments thereafter. The second award is a standard stock option to purchase 8,952 shares at an exercise price of $26.18, following the same three-year vesting structure and expiring August 13, 2036.

The third new award is a performance stock option covering 29,159 shares at the same $26.18 exercise price. According to the filing, these shares vest over a performance period ending on the earlier of a change in control or the 10-year anniversary of the grant date, and are subject to achievement of stock-price hurdles of $50.00, $75.00, and $100.00 per share, with time-based vesting of one-third on the first anniversary of the grant date and the remaining two-thirds in 24 substantially equal monthly installments thereafter.

What Was Disclosed

Andrews's Form 4 reported the vesting and partial tax-related disposition of 5,233 performance stock units, plus new grants of 4,975 RSUs, an 8,952-share stock option, and a 29,159-share performance stock option, all dated August 14, 2026. Her resulting direct share ownership stands at 38,910 shares.